Descrizione del progetto
Una tecnologia di chip per una coltura in vitro di mini organi vascolarizzati
La ricerca e lo sviluppo di farmaci dipendono in larga misura da modelli animali, ma la fisiologia e la biologia differenti potrebbe complicare l’interpretazione dei risultati. I modelli di cellule in vitro sono semplicistici e non riflettono la fisiologia del tessuto, evidenziando la necessità di modelli migliori. Il progetto OrganoPlate Graft, finanziato dall’UE, creerà il primo metodo di coltura in vitro ad alta produttività per un tessuto vascolarizzato. Ricorrendo a una tecnologia di organo su chip sviluppata in precedenza, gli scienziati saranno in grado di coltivare e monitorare i mini organi tridimensionali in vitro in modo controllato. L’attuazione di questo sistema consentirà di progettare esperimenti innovativi all’interno della ricerca e dello sviluppo, nonché per finalità cliniche.
Obiettivo
PROBLEM – The drug development cycle, from basic research to testing efficacy, toxicity, and safety of new therapeutics, is largely depending on animal models. However animal biology and pathology differ from human biology at crucial points. The sector is aware of the significant complications in their usage, but lacks better alternatives. Highly advanced technology exists for the culture of cell systems, organs, tumors, etc. outside the body (‘in vitro’). However, the existing culture models lack functional blood vessels – a vital structure inside the body (‘in vivo’). There is a great unmet need for better models of human biology, to speed up both basic research on human biology as well as the development of novel, much needed therapeutic solutions. SOLUTION – OrganoPlate Graft involves the development to market readiness of the first high-throughput in vitro culture method for vascularized tissue that is unrivalled by the available in vitro options. An extensive proof of concept (PoC) for this method has been obtained. The new product will be launched within 6-months post-project and, for the first time, allow for the study and manipulation of human tissues with functional human vascularization. COMPANY – Founded in 2013, the Dutch SME MIMETAS was the first party to commercially exploit organ-on-a-chip technology that enables accurately controlled and monitored in vitro cultivation 3D ‘mini-organs’. MIMETAS currently employs > 60 professionals, generates year-on year multi-million revenues, and is projected to be profitable as of 2020. RESULTS – The results of the 2-year OrganoPlate Graft project will empower Users by aiding them to grow tissues with human vascularization in vitro – enabling the replacement of a wealth of animal experiments and the design of completely novel experiments in research, development and clinical settings. OrganoPlate Graft will cost €3M, employ 10 new FTEs, and is projected to add 40 FTE and >€50M annual revenues to MIMETAS by 2022.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-2
Meccanismo di finanziamento
SME-2 - SME instrument phase 2Coordinatore
2342 DH Oegstgeest
Paesi Bassi
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.